M&A - MESA LABORATORIES INC /CO/

Form Type: 10-K

Filing Date: 2025-05-28

Corporate Action: Acquisition

Type: New

Accession Number: 000143774925018586

Filing Summary: Mesa Laboratories, Inc. reported substantial growth in revenues attributable to its Clinical Genomics division following the acquisition of Agena Bioscience, Inc. on October 20, 2021. Noteworthy is the impact of the Tax Cut and Jobs Act of 2017, which necessitated the capitalization of research and development costs, affecting deferred tax assets and cash tax liabilities. The report outlines that the results include contributions from GKE starting from the acquisition in fiscal year 2024, with revenues of $9,289 included in the Sterilization and Disinfection Control division for the year ending March 31, 2024, and an additional $24,815 for the year ending March 31, 2025. The management discussion highlights that operating expenses and segment revenues are aligned with GAAP principles, emphasizing effective performance across its various business segments including Corporate and Other, which report unallocated corporate expenses. Furthermore, the company’s accumulated other comprehensive (loss) income is also discussed, alongside significant changes in segment cost structures following the historical acquisitions. The company’s total outstanding shares as of May 21, 2025, were reported at 5,455,437 with a market value of $686 million as estimated based on stock closing prices.